Stevenage, UK, January 7 2013 – Stevenage Bioscience Catalyst (SBC), the UK’s
first open innovation (OI) bioscience campus, will be debating the role of OI across
the biotech and medtech sectors at the prestigious Biotech Showcase 2013 in San
Francisco. In the workshop on January 9, 'Open Innovation: Driver of Future
Healthcare Solutions?', CEO Martino Picardo will be joined by speakers from the
venture capital and pharmaceutical industries.
The panel, chaired by David Flores, President and CEO of Biocentury, is expected to
cover issues such as how to use OI to tackle difficult research questions, as well as
how to protect competitiveness and keep venture capital funders on board.
Crowdfunding, the area of expertise for panellist Poliwogg Inc, and the latest OI
initiatives will also be discussed. Other participants include GlaxoSmithKline,
Syncona Partners (recently launched with £200m of initial capital from the Wellcome
Trust), and PureTech Ventures.
Biotech Showcase 2013 is an investor and partnering conference running from
January 7-9 in parallel with the JP Morgan Healthcare Conference in San Francisco.
It is expected to feature over 230 presentations, with in excess of 1500 attendees.
For more information, please contact:
Stevenage Bioscience Catalyst
Martino Picardo, CEO +44 (0)1438 906906
Emma Palmer Foster, Strategic Communications Consultant +44 (0)7880 787185
About Stevenage Bioscience Catalyst
Stevenage Bioscience Catalyst is the UK’s first open innovation bioscience campus,
pioneering a unique culture to drive early stage bioscience technology and company
development, and building a thriving community. It is backed by £38m of funding from its
founding partners – GlaxoSmithKline, the Wellcome Trust, the Department for Business,
Innovation and Skills, the Technology Strategy Board
and the former East of England
Development Agency. Consisting of an Incubator, an Accelerator and a Hub, covering
60,000 sq ft of laboratory, office and networking space, the independent facility houses a range of companies, from virtual and start-up firms to those which are more established, as
well as other organisations. Located on the GlaxoSmithKline Stevenage site, Stevenage
Bioscience Catalyst is in the unique position of operating in proximity to the expertise and
resources of a major pharmaceutical company, close to both London and Cambridge. For
more information, please go to www.stevenagecatalyst.com.
About Open Innovation
Firms using Open Innovation (OI) combine their own R&D with externally sourced ideas and
expertise. OI is characterised by highly effective use of connections and networks to
exchange knowledge and ideas, external partners being involved at all stages of product
development, equitable win-win business relationships, and new business models to
maximise the value of intellectual property and other assets. Examples in various sectors
have shown that the benefits of OI include reduced time to market for new products and
services, access to new markets, improved innovation success rates and increased profits.
SBC will promote use of Open Innovation within the life sciences sector, connecting SMEs
with an active network consisting of GlaxoSmithKline and its other stakeholders, academia,
charities, other businesses and funding bodies. The term ‘Open Innovation’ and related
research into its practice have been developed extensively by Professor Henry Chesbrough,
Executive Director of the Program in Open Innovation at the University of California,
About Stevenage Bioscience Catalyst's stakeholders
Stevenage Bioscience Catalyst's stakeholders are GlaxoSmithKline (www.gsk.com), the
Wellcome Trust (www.wellcome.ac.uk), the Department of Business, Innovation and Skills
(www.bis.gov.uk), the Technology Strategy Board (www.innovateuk.org) and the former East
of England Development Agency (www.eeda.org.uk)